## **Original Article**

## Cardiometabolic risk profile in cases of Acute Stroke.

Akash Daswaney<sup>1</sup>, Sam Benjamin Rodrigues<sup>1</sup>, Sourya Acharya<sup>2</sup>, Samarth Shukla<sup>3</sup>

<sup>1</sup>MBBS Student, Primary researchers <sup>2</sup>Professor, Dept. of Medicine

Professor, Dept. of Medicin

<sup>3</sup>Professor, Dept. of Pathology

J.N. Medical College, DMIMS (DU) Sawangi (Meghe), Wardha, Maharashtra

Address for Correspondence: Dr. Sourya Acharya

Professor, Dept. of Medicine, J.N. Medical College, DMIMS (DU), Sawangi (Meghe), Wardha-442001, Maharashtra

Abstract:

Aim: To study the cardiometabolic risk profile of acute stroke.

Material and Methods: This prospective crossectional study was carried out in Jawarhalal Nehru Medical College AVBR Hospital, which is a 1280 bedded tertiary care hospital situated in Wardha district of Central India. One hundred consecutive cases of acute cerebrovacsular episodes (diagnosed by classical clinical features and confirmed by neuroimaging) who were admitted in the Medicine Ward/ ICU were included in the study. MetS was diagnosed by modified NCEP ATP III criteria. Parameters of cardiometabolic risk factors were compared between stroke patients with metabolic syndrome and without metabolic syndrome.

Results: In this study, recurrent stroke occurred significantly in metabolic syndrome group (p<0.05). Individually all metabolic syndrome parameters were associated significantly in acute stroke patients irrespective of the nature of the stroke (ischaemic vs haemorrhagic). When ischaemic and haemorrhagic stroke were separately compared we found no statistically significant correlation between the cardiometabolic risk parameters, suggesting that all the risk factors are distributed equally in both forms of stroke.

Conclusion: As the frequency of metabolic syndrome in stroke patients is high. It is important to change the lifestyle in order to prevent cardiovascular diseases and stroke.

Keywords: stroke, metabolic syndrome, cardiovascular, cardiometabolic, ischaemia, haemorrhage

#### **Introduction :**

Cerebrovascular diseases are the leading causes of mortality and morbidity in men and women in industrialized countries. <sup>[1-3]</sup> It is the main reason of functional disability. Stroke is the most common reason of disability affects of more than 700 000 individuals and the third cause of death in the world per year. <sup>[2]</sup> The consequent post stroke neurologic sequelae remains persistent in 90% patients, one third of the patients suffer permanent disability. <sup>[1,2]</sup> Cognitive impairment and dementia are the most important post stroke phenomenas. <sup>(3)</sup>. Hypertension together with age are leading risk factors for silent or symptomatic cerebrovascular disease. <sup>[4-6]</sup> The risk of cerebral hemorrhage in hypertensive patients is 3.9 times higher than in non-hypertensive individuals.

Dyslipidemia, hypertension and obesity are atherogenic risk factors frequently found in type 2 diabetes patients. All these add to the burden of risk factors for stroke. <sup>[7,8]</sup> Cigarette smoking is an independent predictor of cerebrovascular disease in both men and women. <sup>[9].</sup> Smokers have a relative risk of ischemic stroke of 1.92 times higher as compared to non-smokers. Relationships between dyslipidemia and stroke have not been consistently elucidated. <sup>[10]</sup>

Metabolic syndrome (MetS) is defined (modified NCEP- ATP III) as the presence of three or more of the following: (1) abdominal obesity as determined by waist circumference > 90 cm and > 80 cm for women; (2) triglycerides  $\geq$  150 mg/dL; (3) HDL cholesterol < 40 mg/dL for men and < 50 mg/dL for women; (4) systolic blood pressure  $\geq$  130 mm Hg and

## Dr. Sourya Acharyaet.al / Cardiometabolic risk profile in cases of Acute Stroke.

diastolic blood pressure  $\geq 85$  mmHg; and (5) fasting glucose  $\geq$  110 mg/dL . The metabolic syndrome is a predictor of coronary heart disease, cardiovascular disease (which includes coronary heart disease and stroke) and all-cause mortality. Also, the risk of stroke is higher for patients presenting some of the diseases included in the metabolic syndrome. <sup>[11]</sup> In one study the age-standardized prevalence rates of metabolic syndrome in india were 33.5% overall, 24.9 % in males and 42.3% in females. Older age, female gender, general obesity, inadequate fruit intake, hypercholesterolemia, and middle-to-high socioeconomic status significantly contributed to increased risk of metabolic syndrome. <sup>[12]</sup>

MetS is associated with different kind of diseases such as development of myocardial ischemia, ischemic stroke, extra and intracranial atherosclerotic, and asymptomatic carotid atherosclerotic plaques. <sup>[13-15]</sup> Some studies showed that lifestyle can affect on the MetS occurrence, so the risk of ischemic stroke decreases consequently by changing it. <sup>[16]</sup> This study was done to assess the cardiometabolic profile in acute stroke patients.

## Aim:

To study the cardiometabolic risk profile of acute stroke .

## **Objectives:**

- 1. To estimate the proportion/ frequency of modifiable risk factors in stroke patients
- 2. To estimate the proportion/ frequency of metabolic syndrome parameters in patients of acute stroke.

## Materials and Methods :

This prospective crossectional study was carried out in Jawarhalal Nehru Medical College AVBR Hospital, which is a 1280 bedded tertiary care hospital situated in Wardha district of Central India. Duration of the study was 2 months. Ethical committee clearance was obtained before starting the study.

One hundred consecutive cases of acute cerebrovacsular episodes (diagnosed by classical clinical features and confirmed by neuroimaging) who were admitted in the Medicine Ward/ ICU were included in the study. Detailed history including family history, history of hypertension, diabetes, coronary artery disease, dyslipidaemia, alcoholism, smoking was taken.

Clinical examination and anthropometry (BMI, Waist circumference) was taken. Physical measurements were done by trained medical staff with standardized methods. The weight was measured by a digital scale, with minimum necessary clothing, and recorded to the nearest 0.5 kg. Height was measured in a standing position, without shoes, to the nearest 0.5 cm. BMI was calculated and recorded as weight in kg divided by height in meter squared. While the subjects were standing, WC was measured by a tape at a level midway between the lower rib margin and iliac crest. <sup>[17]</sup>

Appropriate investigations in form of FBS, Lipid Profile, ECG was done.

## Exclusion criteria :

- 1. Patients not willing to participate
- 2. CVE patients in coma.

The metabolic syndrome was assessed by modified modified NCEP ATP III criteria. <sup>[18]</sup>

## Statistical analysis ;

Statistical analysis was done by using descriptive and inferential statistics using Chi- Square test, Student 't' test and software used in analysis was SPSS 24.0 version and Graph Pad, p<0.05 was considered as significant.

## **Results :**

# Table 1 : Baseline characteristics of Acute Stroke patients with and without Metabolic Syndrome .

Metabolic         Non Metabolic         Test value         p-value           Age(yrs)         55.93±10.31         55.66±14.96         0.09         0.92,NS           Age Range         29-72 yrs         17-87 yrs         0.09         0.92,NS           Gender          3.95         0.046,S           Male         20         57         3.95         0.046,S           Female         11         12         3.95         0.046,S           Per Capita Income         3514.14±4008.75         2464.91±2121.38         5.21         0.004,S           Smoking         6(19.35%)         16(23.19%)         0.48         0.48,NS           Alcohol Abuse         9(29.03%)         23(33.33%)         0.37         0.54,NS           H/O Addiction         16(51.61%)         38(55.07%)         0.18         0.67,NS           Illicit Drug Use         0(0%)         1(1.45%)         1.00         0.31,NS           Previous Stroke/         6(19.35%)         6(8.70%)         4.15         0.0001,S           Dyslipidaemia         7(22.58%)         4(5.80%)         11.66         0.0006,S           DM         13(41.94%)         8(11.59%)         22.83         0.0001,S           CvS Profile <th></th> <th>Mathalia</th> <th>Mar Mathal</th> <th>Tetal</th> <th></th>		Mathalia	Mar Mathal	Tetal	
Age Range         29-72 yrs         17-87 yrs         0.09         0.92,NS           Gender		Metabolic	Non Metabolic	Test value	p-value
Age Kange         29-72 yrs         17-87 yrs         Annotation           Gender				0.09	0.92,NS
Male         20         57         3.95         0.046,S           Female         11         12         3.95         0.046,S           History               Per Capita Income         3514.14±4008.75         2464.91±2121.38         5.21         0.004,S           Smoking         6(19.35%)         16(23.19%)         0.48         0.48,NS           Alcohol Abuse         9(29.03%)         23(33.33%)         0.37         0.54,NS           H/O Addiction         16(51.61%)         38(55.07%)         0.18         0.67,NS           Illicit Drug Use         0(0%)         1(1.45%)         1.00         0.31,NS           Previous Stroke/         6(19.35%)         6(8.70%)         4.15         0.0001,S           Neurological            0.001,S           Dyslipidaemia         7(22.58%)         4(5.80%)         11.66         0.0006,S           DM         13(41.94%)         8(11.59%)         22.83         0.0001,S           Uslipidaemia         7(22.58%)         4(5.80%)         0.14         0.70,NS           Disease            0.014,S         0.012,S           CAD		29-72 yrs	17-87 yrs	0.07	
Female         11         12         3.95         0.046,S           History					
Female         11         12         11         12           History	Male			3.05	0.046,S
Per Capita Income         3514.14±4008.75         2464.91±2121.38         5.21         0.004,S           Smoking         6(19.35%)         16(23.19%)         0.48         0.48,NS           Alcohol Abuse         9(29.03%)         23(33.33%)         0.37         0.54,NS           H/O Addiction         16(51.61%)         38(55.07%)         0.18         0.67,NS           Illicit Drug Use         0(0%)         1(1.45%)         1.00         0.31,NS           Previous Stroke/         6(19.35%)         6(8.70%)         4.15         0.041,S           Neurological         Disease         0         0.001,S         0.0001,S           Dyslipidaemia         7(22.58%)         4(5.80%)         11.66         0.0006,S           DM         13(41.94%)         8(11.59%)         22.83         0.0001,S           CVS Profile            0.70,NS           Disease          0(0%)         1(1.45%)         1.00         0.31,NS           Cardiomyopathy         0(0%)         1(1.45%)         0.014         0.70,NS           Disease           0.00%         4(5.80%)         6.18         0.012,S           CAD         1(3.23%)         3(4.35%)	Female	11	12	3.35	
Smoking         6(19.35%)         16(23.19%)         0.48         0.48,NS           Alcohol Abuse         9(29.03%)         23(33.33%)         0.37         0.54,NS           H/O Addiction         16(51.61%)         38(55.07%)         0.18         0.67,NS           Illicit Drug Use         0(0%)         1(1.45%)         1.00         0.31,NS           Previous Stroke/         6(19.35%)         6(8.70%)         4.15         0.041,S           Neurological         Disease	History				
Alcohol Abuse         9(29.03%)         23(33.33%)         0.37         0.54,NS           H/O Addiction         16(51.61%)         38(55.07%)         0.18         0.67,NS           Illicit Drug Use         0(0%)         1(1.45%)         1.00         0.31,NS           Previous Stroke/         6(19.35%)         6(8.70%)         4.15         0.041,S           Neurological         Disease         0         0.011,66         0.0001,S           Dyslipidaemia         7(22.58%)         4(5.80%)         11.66         0.0006,S           DM         13(41.94%)         8(11.59%)         22.83         0.0001,S           CVS Profile         0         0         0.31,NS         0.001,S           Valvular Heart         1(3.23%)         3(4.35%)         0.14         0.70,NS           Disease         0         00%)         1(1.45%)         1.00         0.31,NS           Atrial Fibrillation         0(0%)         1(1.45%)         1.00         0.31,NS           CAD         1(3.23%)         3(4.35%)         0.14         0.70,NS           Meight(kg)         62.54±12.94         59.52±10.98         1.20         0.23,NS           Weight(kg)         62.54±12.94         59.52±10.98         1.2	Per Capita Income	3514.14±4008.75	2464.91±2121.38	5.21	0.004,S
H/O Addiction         16(51.61%)         38(55.07%)         0.18         0.67,NS           Illicit Drug Use         0(0%)         1(1.45%)         1.00         0.31,NS           Previous Stroke/         6(19.35%)         6(8.70%)         4.15         0.041,S           Neurological         Disease         0         0.0001,S         0.0001,S           Dyslipidaemia         7(22.58%)         4(5.80%)         11.66         0.0006,S           DM         13(41.94%)         8(11.59%)         22.83         0.0001,S           Valvular Heart         1(3.23%)         3(4.35%)         0.14         0.70,NS           Disease         0         0(0%)         1(1.45%)         1.00         0.31,NS           Valvular Heart         1(3.23%)         3(4.35%)         0.14         0.70,NS           Disease         0         00%)         4(5.80%)         6.18         0.012,S           CAD         1(3.23%)         3(4.35%)         0.14         0.70,NS           Atrial Fibrillation         0(0%)         4(5.80%)         6.18         0.012,S           CAD         1(3.23%)         3(4.35%)         0.14         0.70,NS           Meight(kg)         62.54±12.94         59.52±10.98	Smoking	6(19.35%)	16(23.19%)	0.48	0.48,NS
Illicit Drug Use         0(0%)         1(1.45%)         1.00         0.31,NS           Previous Stroke/         6(19.35%)         6(8.70%)         4.15         0.041,S           Neurological         Disease         0         0.041,S         0.041,S           Hypertension         26(83.87%)         22(31.88%)         55.50         0.0001,S           Dyslipidaemia         7(22.58%)         4(5.80%)         11.66         0.0006,S           DM         13(41.94%)         8(11.59%)         22.83         0.0001,S           CVS Profile         0         0.14         0.70,NS           Disease         0         1(1.45%)         1.00         0.31,NS           Atrial Fibrillation         0(0%)         1(1.45%)         0.14         0.70,NS           Disease         0         00%)         1(1.45%)         1.00         0.31,NS           Atrial Fibrillation         0(0%)         4(5.80%)         6.18         0.012,S           CAD         1(3.23%)         3(4.35%)         0.14         0.70,NS           Mutrial Fibrillation         0(0%)         4(5.80%)         6.18         0.012,S           CAD         1(3.23%)         3(4.35%)         0.14         0.70,NS <tr< td=""><td>Alcohol Abuse</td><td>9(29.03%)</td><td></td><td>0.37</td><td>0.54,NS</td></tr<>	Alcohol Abuse	9(29.03%)		0.37	0.54,NS
Previous Stroke/ Neurological Disease         6(19.35%)         6(8.70%)         4.15         0.041,S           Mypertension         26(83.87%)         22(31.88%)         55.50         0.0001,S           Dyslipidaemia         7(22.58%)         4(5.80%)         11.66         0.0006,S           DM         13(41.94%)         8(11.59%)         22.83         0.0001,S           CVS Profile               Valvular Heart         1(3.23%)         3(4.35%)         0.14         0.70,NS           Disease            0.012,S           Cardiomyopathy         0(0%)         1(1.45%)         1.00         0.31,NS           Atrial Fibrillation         0(0%)         4(5.80%)         6.18         0.012,S           CAD         1(3.23%)         3(4.35%)         0.14         0.70,NS           Meight(kg)         62.54±12.94         59.52±10.98         1.20         0.23,NS           Height(cms)         162.71±10.89         163.26±7.77         0.28         0.77,NS           BMI(kg/m2)         23.15±3.50         21.72±3.14         2.02         0.046,S           WC(cm)-Male         108.30±14.40         96.96±12.51         3.35         0.0	H/O Addiction	16(51.61%)	38(55.07%)	0.18	0.67,NS
Neurological Disease         26(83.87%)         22(31.88%)         55.50         0.0001,S           Hypertension         26(83.87%)         22(31.88%)         55.50         0.0006,S           Dyslipidaemia         7(22.58%)         4(5.80%)         11.66         0.0006,S           DM         13(41.94%)         8(11.59%)         22.83         0.0001,S           CVS Profile               Valvular Heart         1(3.23%)         3(4.35%)         0.14         0.70,NS           Disease            0.012,S           Cardiomyopathy         0(0%)         1(1.45%)         1.00         0.31,NS           Atrial Fibrillation         0(0%)         4(5.80%)         6.18         0.012,S           CAD         1(3.23%)         3(4.35%)         0.14         0.70,NS           Anthropometry                Weight(kg)         62.54±12.94         59.52±10.98         1.20         0.23,NS           Height(cms)         162.71±10.89         163.26±7.77         0.28         0.77,NS           BMI(kg/m2)         23.15±3.50         21.72±3.14         2.02         0.046,S <t< td=""><td>Illicit Drug Use</td><td>0(0%)</td><td>1(1.45%)</td><td>1.00</td><td>0.31,NS</td></t<>	Illicit Drug Use	0(0%)	1(1.45%)	1.00	0.31,NS
Disease         26(83.87%)         22(31.88%)         55.50         0.0001,S           Dyslipidaemia         7(22.58%)         4(5.80%)         11.66         0.0006,S           DM         13(41.94%)         8(11.59%)         22.83         0.0001,S           CVS Profile           0.14         0.70,NS           Disease           0.00%         0.14         0.70,NS           Cardiomyopathy         0(0%)         1(1.45%)         1.00         0.31,NS           Atrial Fibrillation         0(0%)         4(5.80%)         6.18         0.012,S           CAD         1(3.23%)         3(4.35%)         0.14         0.70,NS           Mtrial Fibrillation         0(0%)         4(5.80%)         6.18         0.012,S           CAD         1(3.23%)         3(4.35%)         0.14         0.70,NS           Mthropometry            0.012,S           Weight(kg)         62.54±12.94         59.52±10.98         1.20         0.23,NS           Height(cms)         162.71±10.89         163.26±7.77         0.28         0.77,NS           BMI(kg/m2)         23.15±3.50         21.72±3.14         2.02         0.046,S <t< td=""><td>Previous Stroke/</td><td>6(19.35%)</td><td>6(8.70%)</td><td>4.15</td><td>0.041,S</td></t<>	Previous Stroke/	6(19.35%)	6(8.70%)	4.15	0.041,S
Hypertension         26(83.87%)         22(31.88%)         55.50         0.0001,S           Dyslipidaemia         7(22.58%)         4(5.80%)         11.66         0.0006,S           DM         13(41.94%)         8(11.59%)         22.83         0.0001,S           CVS Profile           0.14         0.70,NS           Disease           0.00%         0.14         0.70,NS           Cardiomyopathy         0(0%)         1(1.45%)         1.00         0.31,NS           Atrial Fibrillation         0(0%)         4(5.80%)         6.18         0.012,S           CAD         1(3.23%)         3(4.35%)         0.14         0.70,NS           Mtrial Fibrillation         0(0%)         4(5.80%)         6.18         0.012,S           CAD         1(3.23%)         3(4.35%)         0.14         0.70,NS           Mthropometry           0.012,S         0.012,S           Weight(kg)         62.54±12.94         59.52±10.98         1.20         0.23,NS           Height(cms)         162.71±10.89         163.26±7.77         0.28         0.77,NS           BMI(kg/m2)         23.15±3.50         21.72±3.14         2.02         0.046,S	Neurological				
Dyslipidaemia         7(22.58%)         4(5.80%)         11.66         0.0006,S           DM         13(41.94%)         8(11.59%)         22.83         0.0001,S           CVS Profile                    0.0001,S                0.0001,S               0.0001,S   <	Disease				
DM         13(41.94%)         8(11.59%)         22.83         0.0001,S           CVS Profile	Hypertension	26(83.87%)	22(31.88%)	55.50	0.0001,S
CVS Profile         0.001/09         0.001/09           Valvular Heart         1(3.23%)         3(4.35%)         0.14         0.70,NS           Disease         000%         1(1.45%)         1.00         0.31,NS           Atrial Fibrillation         0(0%)         4(5.80%)         6.18         0.012,S           CAD         1(3.23%)         3(4.35%)         0.14         0.70,NS           Atrial Fibrillation         0(0%)         4(5.80%)         6.18         0.012,S           CAD         1(3.23%)         3(4.35%)         0.14         0.70,NS           Anthropometry         0         100         0.23,NS           Weight(kg)         62.54±12.94         59.52±10.98         1.20         0.23,NS           Height(cms)         162.71±10.89         163.26±7.77         0.28         0.77,NS           BMI(kg/m2)         23.15±3.50         21.72±3.14         2.02         0.046,S           WC(cm)-Male         108.30±14.40         96.96±12.51         3.35         0.001,S	Dyslipidaemia	7(22.58%)	4(5.80%)	11.66	0.0006,S
Valvular Heart Disease         1(3.23%)         3(4.35%)         0.14         0.70,NS           Cardiomyopathy         0(0%)         1(1.45%)         1.00         0.31,NS           Atrial Fibrillation         0(0%)         4(5.80%)         6.18         0.012,S           CAD         1(3.23%)         3(4.35%)         0.14         0.70,NS           Meight(kg)         62.54±12.94         59.52±10.98         1.20         0.23,NS           Height(cms)         162.71±10.89         163.26±7.77         0.28         0.77,NS           BMI(kg/m2)         23.15±3.50         21.72±3.14         2.02         0.046,S           WC(cm)-Male         108.30±14.40         96.96±12.51         3.35         0.001,S	DM	13(41.94%)	8(11.59%)	22.83	0.0001,S
Disease         0(0%)         1(1.45%)         1.00         0.31,NS           Atrial Fibrillation         0(0%)         4(5.80%)         6.18         0.012,S           CAD         1(3.23%)         3(4.35%)         0.14         0.70,NS           Anthropometry               Weight(kg)         62.54±12.94         59.52±10.98         1.20         0.23,NS           Height(cms)         162.71±10.89         163.26±7.77         0.28         0.77,NS           BMI(kg/m2)         23.15±3.50         21.72±3.14         2.02         0.046,S           WC(cm)-Male         108.30±14.40         96.96±12.51         3.35         0.001,S	CVS Profile				
Cardiomyopathy         0(0%)         1(1.45%)         1.00         0.31,NS           Atrial Fibrillation         0(0%)         4(5.80%)         6.18         0.012,S           CAD         1(3.23%)         3(4.35%)         0.14         0.70,NS           Anthropometry            0.23,NS           Weight(kg)         62.54±12.94         59.52±10.98         1.20         0.23,NS           Height(cms)         162.71±10.89         163.26±7.77         0.28         0.77,NS           BMI(kg/m2)         23.15±3.50         21.72±3.14         2.02         0.046,S           WC(cm)-Male         108.30±14.40         96.96±12.51         3.35         0.001,S	Valvular Heart	1(3.23%)	3(4.35%)	0.14	0.70,NS
Atrial Fibrillation         0(0%)         4(5.80%)         6.18         0.012,S           CAD         1(3.23%)         3(4.35%)         0.14         0.70,NS           Anthropometry	Disease				
CAD         1(3.23%)         3(4.35%)         0.14         0.70,NS           Anthropometry <th< th=""> <th< th="">          &lt;</th<></th<>	Cardiomyopathy	0(0%)	1(1.45%)	1.00	0.31,NS
Anthropometry         99.52±10.98         1.20         0.23,NS           Weight(kg)         62.54±12.94         59.52±10.98         1.20         0.23,NS           Height(cms)         162.71±10.89         163.26±7.77         0.28         0.77,NS           BMI(kg/m2)         23.15±3.50         21.72±3.14         2.02         0.046,S           WC(cm)-Male         108.30±14.40         96.96±12.51         3.35         0.001,S	Atrial Fibrillation	0(0%)	4(5.80%)	6.18	0.012,S
Weight(kg)         62.54±12.94         59.52±10.98         1.20         0.23,NS           Height(cms)         162.71±10.89         163.26±7.77         0.28         0.77,NS           BMI(kg/m2)         23.15±3.50         21.72±3.14         2.02         0.046,S           WC(cm)-Male         108.30±14.40         96.96±12.51         3.35         0.001,S	CAD	1(3.23%)	3(4.35%)	0.14	0.70,NS
Height(cms)         162.71±10.89         163.26±7.77         0.28         0.77,NS           BMI(kg/m2)         23.15±3.50         21.72±3.14         2.02         0.046,S           WC(cm)-Male         108.30±14.40         96.96±12.51         3.35         0.001,S	Anthropometry				
BMI(kg/m2)         23.15±3.50         21.72±3.14         2.02         0.046,S           WC(cm)-Male         108.30±14.40         96.96±12.51         3.35         0.001,S	Weight(kg)	62.54±12.94	59.52±10.98	1.20	0.23,NS
WC(cm)-Male 108.30±14.40 96.96±12.51 3.35 0.001,S	Height(cms)	162.71±10.89	163.26±7.77	0.28	0.77,NS
	BMI(kg/m2)	23.15±3.50	21.72±3.14	2.02	0.046,S
WC(cm)-Female 98.72±7.69 93.66±20.57 0.76 0.46,NS	WC(cm)-Male	108.30±14.40	96.96±12.51	3.35	0.001,S
	WC(cm)-Female	98.72±7.69	93.66±20.57	0.76	0.46,NS

#### Dr. Sourya Acharyaet.al / Cardiometabolic risk profile in cases of Acute Stroke.

Blood						
Pressure						
DBP(mmHg)	145.90±14.59	125.72±14	6.57	0.0001,S		
SBP(mmHg)	92.48±7.99	82.69±8.45	5.44	0.0001,S		
Blood Sugar						
PMBS	161.29±57.75	115.45±28.93	5.29	0.0001,S		
FBS	127.54±47.89	90.75±26.37	4.94	0.0001,S		
HDL Male	36.35±13.68	33.59±9.05	1.01	0.31,NS		
HDL Female	37.63±11.34	39.5±9.29	0.43	0.67,NS		
TG	163.4±90.75	110.50±43.41	3.95	0.0001,S		
Diagnosis: Type of Stroke						
Ischaemic	19(61.29%)	42(60.87%)	0.001	0.96.NS		
Haemorrhagic	12(38.71%)	27(39.13%)	0.001	0.90,113		

## **Discussion :-**

This study aims at finding and identifying the role of metabolic syndrome in Cerebrovascular disease. As per our study, there was a higher incidence of stroke in males and females who met the modified NCEP ATPIII criteria for metabolic syndrome compared to males and females who didn't have metabolic syndrome. This can be compared to a study that estimated the risk of stroke in middle aged men diagnosed with metabolic syndrome (as defined by the NCEP criteria) which found that these men had a 2.05-fold (95% CI, 1.03 to 4.11; P=0.042) risk for all strokes and 2.41-fold (95% CI, 1.12 to 5.32; P=0.025) risk for ischemic stroke, after adjusting for socioeconomic status, smoking, alcohol, and family history of coronary heart disease. <sup>[19]</sup>

Our study also found that there was an increased incidence of cerebrovascular episodes in metabolic syndrome patients with history of previous stroke. This finding was supported by some other studies. The ACROSS, China Study that correlated metabolic syndrome and stroke recurrence found that at the one-year follow-up, a total of 21.5% of subjects with metabolic syndrome had stroke recurrence compared to 12.4% of those without metabolic syndrome. <sup>[20]</sup>

Other studies also support the findings that confirms , MetS as a potential risk factor for minor and major strokes. <sup>[16,21,22]</sup> Similar to some studies, our studied also showed that patients addicted to alcohol, and cigarrete smoking had a higher incidence of ischaemic stroke. <sup>[9,10,12,24]</sup>

In our study Hypertension, Diabetes and Dyslipidemia had no bearings on incidence of ischemic or hemorrhagic stroke when compared separately. Our findings corroborates with other studies that showed higher risk of stroke in MetS patients in both gender compare to controls non metabolic cases.<sup>[25]</sup> As MetS increases intracranial atherosclerosis so can be associated with higher risk of stroke, Ovbiagele et al. showed that half of patients with symptomatic intracranial atherosclerotic disease had metabolic syndrome.<sup>[26]</sup> On the other hand, prevalence of brain silent ischemic lesions increases in MetS independent of other risk factors.<sup>[27]</sup>

The metabolic syndrome is currently more frequent and a large number of people in worldwide are vulnerable, therefore, it is necessary to pay attention about the frequency of this syndrome in different parts of world in order to control the CVD and stroke prevalence, especially in the elderly.

## Conclusion:

As the frequency of metabolic syndrome in stroke patients is high. It is important to change the lifestyle in order to prevent cardiovascular diseases and stroke. Health education, specific protection will be of paramount importance to curtail the burden of these diseases.

#### **References:**

- Catalan Society of Neurology. Official Guidelines for diagnosis and treatment. In: Cerebrovascular Diseases., editor. 2nd ed. Barcelona: Societat Catalana de Neurologia; 2011. pp. 159–240.
- 2. Air EL, Kissela BM. Diabetes, the metabolic syndrome, and ischemic stroke: Epidemiology and possible mechanisms. Diabetes Care. 2007;30:3131–40.
- Kalaria RN. Cerebrovascular disease and mechanisms of cognitive impairment: evidence from clinicopathological studies in humans. Stroke. 2012;43:2526–2534.
- 4. Allen CL, Bayraktutan U. Risk factors for ischaemic stroke. Int J Stroke. 2008;3:105–116
- McGuinness B, Todd S, Passmore AP, Bullock R. Systematic review: Blood pressure lowering in patients without prior cerebrovascular disease for prevention of cognitive impairment and dementia. J Neurol Neurosurg Psychiatry. 2008;79:4–5.
- Mancia G, Bombelli M, Facchetti R, Madotto F, Corrao G, Trevano FQ, Grassi G, Sega R. Long-term prognostic value of blood pressure variability in the general population: results of the Pressioni Arteriose Monitorate e Loro Associazioni Study. Hypertension. 2007;49:1265– 1270.
- 7. Mancia G. Prognostic value of long-term blood pressure variability: the evidence is growing. Hypertension. 2011;57:141–143.
- 8. The European Stroke Organisation (ESO) Executive Committee and the ESO Writing Committee. Guidelines for management of ischaemic stroke and transient ischaemic attack 2008. Cerebrovasc Dis. 2008;25:457– 507.
- Burns DM. Epidemiology of smoking-induced cardiovascular disease. Prog Cardiovasc Dis. 2003;46:11– 29.
- 10. Hankey GJ. Potential new risk factors for ischemic stroke: what is their potential? Stroke.2006;37:2181–2188.
- Brickman AM, Reitz C, Luchsinger JA, Manly JJ, Schupf N, Muraskin J, DeCarli C, Brown TR, Mayeux R. Longterm blood pressure fluctuation and cerebrovascular

## Dr. Sourya Acharyaet.al / Cardiometabolic risk profile in cases of Acute Stroke.

disease in an elderly cohort. Arch Neurol. 2010;67:564–569.

- Prasad DS, Kabir Z, Dash AK, Das BC. Prevalence and risk factors for metabolic syndrome in Asian Indians: A community study from urban Eastern India J Cardiovasc Dis Res. 2012 Jul-Sep; 3(3): 204–211. doi: 10.4103/0975-3583.98895
- 13. Al Suwaidi J, Zubaid M, El Menyar AA, Singh R, Rashed W, Ridha M, et al. Prevalence of the metabolic syndrome in patients with acute coronary syndrome in six middle eastern countries. J Clin Hypertens (Greenwich) 2010;12:890–9.
- 14. Aoki J, Uchino K. Treatment of risk factors to prevent stroke. Neurotherapeutics.2011;8:463–74.
- 15. 10. Golden SH, Folsom AR, Coresh J, Sharrett AR, Szklo M, Brancati F. Risk factor groupings related to insulin resistance and their synergistic effects on subclinical atherosclerosis: The atherosclerosis risk in communities study. Diabetes. 2002;51:3069–7.
- Grundy SM. Metabolic syndrome: Connecting and reconciling cardiovascular and diabetes worlds. J Am Coll Cardiol. 2006;47:1093–100.
- 17. National Institutes of Health. The practical guide: identification, evaluation and treatment of overweight and obesity in adults. Bethesda, MD: National Institutes of Health; 2000. p. 80.
- 18. Heng D, Ma S, Lee JJ, Tai BC, Mak KH, Hughes K, Chew SK, Chia KS, Tan CE, Tai ES.Modification of the NCEP ATP III definitions of the metabolic syndrome for use in Asians identifies individuals at risk of ischemic heart disease. Atherosclerosis. 2006 Jun;186(2):367-73. Epub 2005 Aug 19.
- 19. Kurl S, Laukkanen JA, Niskanen L, Laaksonen D, Sivenius J, Nyyssönen K, Salonen JT. Metabolic syndrome and the risk of stroke in middle-aged men. <u>Stroke</u>. 2006;37(3):806-811
- 20. Mi D, Jia Q, Zheng H, Hoff K, Zhao X, Wang C, et al. (2012) Metabolic Syndrome and Stroke Recurrence in Chinese Ischemic Stroke Patients – The ACROSS-China Study. PLoS ONE7(12): e51406.
- 21. Sacco RL<sup>1</sup>, Shi T, Zamanillo MC, Kargman DE.Predictors of mortality and recurrence after hospitalized cerebral infarction in an urban community: the Northern Manhattan Stroke Study. Neurology. 1994 Apr;44(4):626-34.
- 22. Khang YH<sup>1</sup>, Cho SI, Kim HR.Risks for cardiovascular disease, stroke, ischaemic heart disease, and diabetes mellitus associated with the metabolic syndrome using the new harmonised definition: findings from nationally representative longitudinal data from an Asian population. Atherosclerosis. 2010 Dec;213(2):579-85. doi: 10.1016/j.atherosclerosis.2010.09.009. Epub 2010 Sep 18.

- 23. Gill JS, Alexander, Zezulka V, Shipley MJ, Gill SK, Beevers DG. Stroke and Alcohol Consumption. N Engl J Med 1986; 315:1041-1046<u>October 23, 1986</u>
- 24. Helen Hansagi, Anders Romelsjö, Maria Gerhardsson de Verdier, Sven Andréasson, Anders Leifman Alcohol Consumption and Stroke Mortality

20-Year Follow-up of 15 077 Men and Women. Stroke. 1995;26:1768-1773

- 25. Sarrafzadegan N, Gharipour M, Ramezani MA, Rabiei K, Zolfaghar B, Tavassoli AA, et al. Metabolic syndrome and health- related quality of life in Iranian population. J Res Med Sci. 2011;16:254–61.
- 26. Ovbiagele B, Saver JL, Lynn MJ, Chimowitz M. Impact of metabolic syndrome on prognosis of symptomatic intracranial atherostenosis. Neurology. 2006;66:1344–9.
- 27. H , Yamaguchi S, Iijima K, Nagai A, Oguro H. Metabolic syndrome is associated with silent ischemic brain lesions. Stroke. 2008;39:1607–9.